The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...